“Reset” has become a popular word in health.
Sleep better. Exercise regularly. Eat more fruits and vegetables rich in antioxidants… Some people try intermittent fasting; Others focus on reducing added sugar and ultra-processed foods… These habits may influence metabolism, inflammation, and the body’s response to oxidative stress.
But can we actually reset the immune system?
In cell and gene therapy, “immune reset” means something much more specific. CAR cell therapy, originally developed to fight cancer, is now being explored as a way to remove disease-driving immune cells and allow a healthier immune repertoire to rebuild.
Increasingly, researchers are also asking whether this could be accomplished directly inside the patient.
CAR Therapy Is Moving Beyond Curing or Treating Cancer
CAR-T transformed oncology by programming T cells to recognize and attack cells carrying a specific target.
A recent 2026 review in Signal Transduction and Targeted Therapy describes how CAR-based strategies are expanding into autoimmune diseases, chronic infections, fibrosis, transplantation, hemophilia, and senescence-associated disorders.
These diseases are very different, but many share a common feature: persistent pathological cells or cellular programs that the body has difficulty eliminating or controlling. This expands the CAR concept from: “Can we engineer immune cells to kill cancer?” to:
“Can we program immunity to remove or regulate the cells that sustain disease?”
Autoimmune Disease and the Idea of an Immune Reset
Autoimmune disease may become one of the most important frontiers.
Traditional therapies often suppress immune activity repeatedly or continuously. CAR-T takes a different approach: deeply deplete disease-driving immune populations and potentially allow a healthier immune system to re-emerge.
Early clinical experience with CD19-directed CAR-T in systemic lupus erythematosus, systemic sclerosis, inflammatory myositis, and multiple sclerosis has generated substantial interest in this concept of an immune reset.
But this also raises a measurement question:
If disease-associated cells disappear from peripheral blood, has the therapy reached the tissues and cellular compartments that matter the most?
Blood is convenient to measure. Biology is not confined to blood.
In Vivo CAR Changes the Equation
Conventional CAR is primarily an ex vivo process:
cell collection → engineering → expansion → characterization → infusion
In vivo CAR therapy seeks to program immune cells directly inside the patient using targeted delivery technologies.
The potential advantages are compelling: simpler manufacturing, shorter turnaround time, lower cost, and potentially broader access, particularly if CAR therapies expand from relatively small oncology populations into much larger autoimmune-disease populations.
But moving the engineering inside the body changes where the complexity occurs.
With ex vivo CAR therapy, a physical cell product can be characterized before administration.
With in vivo CAR, the therapeutic system must navigate:
delivery → biodistribution → target-cell uptake → CAR expression → cellular expansion → tissue trafficking → biological response
In effect, the patient increasingly becomes part of the manufacturing environment.
As Engineering Moves In Vivo, Measurement Must Follow
That shift introduces questions that go beyond simply asking whether the therapy worked:
- Where did the delivery system go?
- Which cells received the payload?
- How much CAR was expressed, and for how long?
- Did engineered cells reach the relevant tissues?
- Did the expected biological response occur?
- Were unintended genomic changes introduced?
- Where relevant, did vector-derived DNA integrate unexpectedly?
- Are transgene structure or chromosomal rearrangements adequately characterized?
Not every program requires every measurement. The appropriate analytical strategy depends on the delivery system, engineering modality, therapeutic mechanism, and development stage.
But the underlying principle is simple:
We need evidence showing not only what was intended to happen, but what actually happened.
FDA’s recent cellular and gene therapy guidance (August of 2026) similarly emphasizes product characterization, phase-appropriate fit-for-purpose analytical methods, and sensitive quantitative evaluation of biodistribution for gene therapy products.
For emerging in vivo CAR programs, characterization may therefore involve combinations of flow cytometry, NGS, biodistribution analysis, genome-editing verification, integration analysis, structural-variant assessment, and customized bioinformatics.
No single assay answers every question.
From Engineering Cells to Programming Medicine
CAR-T’s first era demonstrated that living immune cells could be engineered to fight cancer.
The next era may involve something broader: removing pathological immune reservoirs, restoring tolerance, remodeling diseased tissues, or temporarily reprogramming immunity directly inside the body.
That opportunity is significant.
But as our ability to program biology becomes more sophisticated, our ability to measure and verify the result must advance with it.
At GeneGoCell, we believe analytical strategy should evolve alongside therapeutic innovation. We support cell and gene therapy programs with customized NGS-based Genome Editing Verification: on-target and nominated off-target verification; genome-wide off-target identification; translocation and structural-variant analysis; vector or donor-template integration analysis; UMI-based low-frequency variant detection, bioinformatics, and high-parameter flow cytometry from research through IND-enabling and clinical-stage development.
The future may be precision medicine. Reliable evidence will help us know whether the program ran as intended.
References
1. Upadhyay S, Cho S, Upmanyu K, Gabr MT. CAR T cell therapy beyond cancer: current status, challenges and future prospects. Signal Transduction and Targeted Therapy. 2026;11:319.
2. U.S. Food and Drug Administration. Frequently Asked Questions — Developing Potential Cellular and Gene Therapy Products: Guidance for Industry. August 2026.
3. Schett G, Xu H. Resetting autoimmune disease with CAR cell therapies. Nature Medicine. 2026;32:2007–2016.
4. Tur C, et al. CD19-CAR T-cell therapy induces deep tissue depletion of B cells. Annals of the Rheumatic Diseases. 2025;84:106–114.
5. Li F. After B Cells Disappear from the Blood: Re-reading Sail’s Science After the J&J Deal. 2026.